Cation-Exchange Membrane Adsorber Patents: Who Leads, Gaps 2026
Cation-Exchange Membrane Adsorber Patents: Filing Trends and Open Claim Space
One assignee dominates the ranking. the leader holds 75 of the records tracked across the five ranked assignees, against a single-digit tail below it. Filings peaked at 43 in 2017. The evidence tracks a further contraction from 3 filings in 2021 to 0 in 2024, a -100% span over those three years; 2025 and 2026 counts are partial due to publication lag and should not be treated as a continuation of that trend.
- 1优时比生物医药有限公司75
- 2健泰科生物技术公司21
- 3弗哈夫曼拉罗切有限公司16
- 4YUSB BIOFARMA SRL2
- 5MEHTA AMIT1
See the full membrane chromatography — cation-exchange membrane adsorbers patent landscape analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents on cation-exchange membrane adsorbers?
One assignee leads the ranked list with 75 of the 111 records tracked in this dataset, well ahead of the other four ranked companies, the smallest of which holds a single record. This is a five-company ranking returned by the data endpoint, not a top-50 or top-100 view, so it should not be read as covering every filer in the field. The concentration at the top suggests a freedom-to-operate review should start with that leading assignee’s portfolio before looking elsewhere.
Is patent filing in cation-exchange membrane adsorbers slowing down?
The tracked data shows filings falling from 3 in 2021 to 0 in 2024, a -100% change over that span, and the peak year so far was 2017 at 43. However, patent publication typically lags filing by around 18 months, so the 2025-26 figures in this dataset are still incomplete and should not be read as evidence of a continued decline. A fairer read is that the field had its most active filing period around 2017 and current activity cannot yet be confirmed either way.
What does EP3309168B1 actually cover?
EP3309168B1, filed by F. Hoffmann-La Roche AG and published 2026-07-08, addresses methods for improved virus removal during protein purification — the same technical thread as the field’s most-cited record, WO2011031397A1, cited 35 times for a related virus-removal method. Anyone designing a purification process with a membrane-based virus-clearance step should review this claim family specifically, since Roche’s related filings account for a meaningful share of the ranked assignee activity. A full claim-by-claim comparison against your process design is the only reliable way to confirm whether a specific implementation falls inside its scope.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Membrane Chromatography — Cation-Exchange Membrane Adsorbers Patent Landscape covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.